Adjuvant Nivolumab Shows Promising Results in Patients with Tumor-Positive Resection Margin Following Chemoradiotherapy and Esophagectomy

Approximately 4-9% of patients had a tumor-positive resection margin after neoadjuvant chemoradiotherapy (ncrt) and esophagectomy. Only a small proportion of patients received adjuvant therapy, despite the association of positive margins with decreased survival. However, a real-world study revealed that 61% of patients were treated with adjuvant immunotherapy (specifically nivolumab) in 2021-2022. Notably, patients who underwent radical esophagectomy had a median overall survival of 16.4 months, and long-term data will explore the potential benefits of nivolumab in improving outcomes.